ELVN logo

Enliven Therapeutics, Inc. (ELVN) Cash from investing

annual CFI:

-$36.00M+$112.42M(+75.75%)
December 31, 2024

Summary

  • As of today (August 22, 2025), ELVN annual cash flow from investing activities is -$36.00 million, with the most recent change of +$112.42 million (+75.75%) on December 31, 2024.
  • During the last 3 years, ELVN annual CFI has fallen by -$35.81 million (-18746.60%).
  • ELVN annual CFI is now -147.05% below its all-time high of $76.52 million, reached on December 31, 2022.

Performance

ELVN Cash from investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

quarterly CFI:

-$183.59M-$185.02M(-12965.38%)
June 30, 2025

Summary

  • As of today (August 22, 2025), ELVN quarterly cash flow from investing activities is -$183.59 million, with the most recent change of -$185.02 million (-12965.38%) on June 30, 2025.
  • Over the past year, ELVN quarterly CFI has dropped by -$149.92 million (-445.34%).
  • ELVN quarterly CFI is now -338.35% below its all-time high of $77.03 million, reached on December 31, 2022.

Performance

ELVN quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

TTM CFI:

-$166.61M-$149.92M(-898.56%)
June 30, 2025

Summary

  • As of today (August 22, 2025), ELVN TTM cash flow from investing activities is -$166.61 million, with the most recent change of -$149.92 million (-898.56%) on June 30, 2025.
  • Over the past year, ELVN TTM CFI has dropped by -$118.20 million (-244.14%).
  • ELVN TTM CFI is now -317.28% below its all-time high of $76.68 million, reached on March 31, 2023.

Performance

ELVN TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Cash from investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

ELVN Cash from investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+75.8%-445.3%-244.1%
3 y3 years-10000.0%-10000.0%-599.5%
5 y5 years-49.6%-466.5%-502.5%

ELVN Cash from investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-147.1%+75.8%-338.4%at low-317.3%at low
5 y5-year-147.1%+75.8%-338.4%at low-317.3%at low
alltimeall time-147.1%+75.8%-338.4%at low-317.3%at low

ELVN Cash from investing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$183.59M(<-9900.0%)
-$166.61M(+898.6%)
Mar 2025
-
$1.43M(+96.3%)
-$16.68M(-53.6%)
Dec 2024
-$36.00M(-75.7%)
$727.00K(-95.1%)
-$36.00M(-1934.7%)
Sep 2024
-
$14.83M(-144.0%)
$1.96M(-104.1%)
Jun 2024
-
-$33.66M(+88.2%)
-$48.41M(-70.9%)
Mar 2024
-
-$17.89M(-146.2%)
-$166.27M(+12.0%)
Dec 2023
-$148.41M(-294.0%)
$38.69M(-208.8%)
-$148.41M(+34.8%)
Sep 2023
-
-$35.55M(-76.5%)
-$110.07M(+47.7%)
Jun 2023
-
-$151.52M(>+9900.0%)
-$74.54M(-197.2%)
Mar 2023
-
-$31.00K(-100.0%)
$76.68M(+0.2%)
Dec 2022
$76.52M
$77.03M(<-9900.0%)
$76.52M(-610.0%)
Sep 2022
-
-$14.00K(-95.4%)
-$15.00M(-37.0%)
Jun 2022
-
-$303.00K(+56.2%)
-$23.82M(+18.3%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$194.00K(-98.7%)
-$20.13M(+1133.4%)
Dec 2021
-$191.00K(-98.9%)
-
-
Dec 2021
-
-$14.49M(+64.1%)
-$1.63M(-104.8%)
Sep 2021
-
-$8.83M(-360.7%)
$34.07M(+4.4%)
Jun 2021
-
$3.39M(-81.5%)
$32.62M(-1127.4%)
Mar 2021
-
$18.30M(-13.7%)
-$3.17M(-81.0%)
Dec 2020
-$16.72M(-30.5%)
$21.21M(-306.3%)
-$16.72M(-55.9%)
Sep 2020
-
-$10.28M(-68.3%)
-$37.93M(+37.2%)
Jun 2020
-
-$32.41M(-781.3%)
-$27.65M(-681.3%)
Mar 2020
-
$4.76M
$4.76M
Dec 2019
-$24.06M(<-9900.0%)
-
-
Dec 2018
$0.00(0.0%)
-
-
Dec 2017
$0.00
-
-

FAQ

  • What is Enliven Therapeutics, Inc. annual cash flow from investing activities?
  • What is the all time high annual CFI for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. annual CFI year-on-year change?
  • What is Enliven Therapeutics, Inc. quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. quarterly CFI year-on-year change?
  • What is Enliven Therapeutics, Inc. TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. TTM CFI year-on-year change?

What is Enliven Therapeutics, Inc. annual cash flow from investing activities?

The current annual CFI of ELVN is -$36.00M

What is the all time high annual CFI for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high annual cash flow from investing activities is $76.52M

What is Enliven Therapeutics, Inc. annual CFI year-on-year change?

Over the past year, ELVN annual cash flow from investing activities has changed by +$112.42M (+75.75%)

What is Enliven Therapeutics, Inc. quarterly cash flow from investing activities?

The current quarterly CFI of ELVN is -$183.59M

What is the all time high quarterly CFI for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high quarterly cash flow from investing activities is $77.03M

What is Enliven Therapeutics, Inc. quarterly CFI year-on-year change?

Over the past year, ELVN quarterly cash flow from investing activities has changed by -$149.92M (-445.34%)

What is Enliven Therapeutics, Inc. TTM cash flow from investing activities?

The current TTM CFI of ELVN is -$166.61M

What is the all time high TTM CFI for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high TTM cash flow from investing activities is $76.68M

What is Enliven Therapeutics, Inc. TTM CFI year-on-year change?

Over the past year, ELVN TTM cash flow from investing activities has changed by -$118.20M (-244.14%)
On this page